Using Artificial Intelligence and Deep Machine Learning to Improve Treatment and Diagnosis of Prostate Cancer

Prof Clare Verrill is a pathologist at the Nuffield Dept of Surgical Sciences, and holds an honorary contract with the Oxford University Hospitals NHS Foundation Trust as a consultant pathologist, specialising in urological pathology. Clare’s primary interests are testis and prostate. Within the Verrill Pathology Group research is focused on digital pathology and image analysis. Clare holds a variety of local and national roles including:  Thames Valley Supraregional Lead for germ cell tumour pathology (since 2011); Chief Investigator of Oxford Radcliffe Biobank (since 2015); RCPath Thames Valley Regional College Advisor (Since June 2017) and Co- lead for Testicular Genomic Clinical Interpretation Partnership (GeCIP) for 100,000 Genomes Project (Genomics England) (since 2015).  She is also the National Cancer Research Institute (NCRI) Cellular Molecular Pathology Initiative (CM-Path) Technology and Informatics Workstream Lead.

By applying Artificial Intelligence (AI) in the cellular pathology setting, Clare and her team hope to deliver benefits for NHS patients in terms of efficiency, accuracy and quality of pathology assessment. Initially, the team hope to develop digital systems that impact clinical care pathways through improving existing workflow efficiency (i.e. potentially reducing turn-around times and making cost savings). In the long term the team hope to develop novel diagnostic strategies relying on machine learning algorithms reliant on tissue morphology features not obvious to a human observer.

One example of Clare’s work is the collaboration with the Finnish Institute of Molecular Medicine (FIMM), which has world leading expertise in digital pathology and image analysis. An image analysis algorithm has been developed, using deep machine learning, which can assess and count tumour infiltrating lymphocytes in testicular germ cell tumours on H&E sections. This helps to avoid the problems of inter-observer variability and subjectivity with pathologist assessment.

Within Oxford Clare collaborates with the Institute of Biomedical Engineering (Prof Jens Rittscher), the Department of Oncology (Prof Andrew Protheroe), the Big Data Institute (Nuffield Department of Medicine) (Dr David Wedge).
National collaborators are Prof Johan de Bono and Dr Clare Turnbull at the Institute of Cancer Research, Dr Matthew J Murray (University of Cambridge), and VisioPharm.

Clare’s research is funded by the National Institute of Health Research (NIHR) Oxford Biomedical Research Centre (BRC), CRUK | Oxford Centre, CRUK, Innovate UK.

Find out more about our research below

Image from an endoscopy video with the detected artefacts highlighted with coloured boxes.

Using AI to improve the quality of endoscopy videos

A multidisciplinary team of researchers has developed a deep-learning framework for improving endoscopy to aid cancer detection.
Women

Using big data in breast cancer research

The Cancer Epidemiology Unit has been using the largest epidemiological data set of its kind to unlock the secrets of breast cancer, what can be done to prevent it, and which women are most likely to develop it

A new FRONTIER for breast cancer

Latest news from FRONTIER, the trial investigating the potential of the radiotracer Fluciclovine in the subtyping and staging of breast cancers

New AI technology to help research into cancer metastasis

DeepScratch is a new AI technology that can be used to analyse how cells move in response to wound, building on the latest advances in deep learning

Using machine-learning approaches to identify blood cancer types

Oxford researchers have outlined the applications of AI in the classification of myeloproliferative neoplasm cancers in a new study

New digital classification method using AI developed for colorectal cancer

A new study from S:CORT demonstrates an easy, cheap way to determine colorectal cancer molecular subtype using AI deep-learning digital pathology technology

Tackling oesophageal cancer early detection challenges through AI

Dr Sharib Ali specialises in the applications of AI to early oesophageal cancer detection

Novel sequencing techniques reveal microRNA influence on prostate cancer development

A new publication collaboration between three Oxford departments uses a novel screening approach to reveal the influence microRNA have on the spread of cancer

NCITA: a new consortium on cancer imaging

NCITA – the UK National Cancer Imaging Translational Accelerator – is a new consortium that brings together world leading medical imaging experts to create an infrastructure for standardising cancer imaging in order to improve its application in clinical cancer treatment.